BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly (ADP-Ribose) polymerase: An issue of potency

Cancer Biology and Therapy

Volumn 4, Issue 9, 2005, Pages 934-936

  McCabe, Nuala ^a   Lord, Christopher J ^a   Tutt, Andrew N J ^a,b   Martin, Niall M B ^c   Smith, Graeme C M ^c   Ashworth, Alan ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c KuDOS Pharmaceuticals Ltd   (United Kingdom)

Author keywords

BRCA2; Breast cancer; Drug sensitivity; Poly (ADP Ribose); Polymerase; Potency

Indexed keywords

8 HYDROXY 2 METHYL 4(3H) QUINAZOLINONE; BRCA2 PROTEIN; KU 0051529; KU 0058684; KU 0058948; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HUMAN CELL;

EID: 27744568392     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.9.2141     Document Type: Article

References (16)

1. Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med 2003; 348:2339-47.
2. Tutt A, Ashworth A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med 2002; 8:571-6.
3. Turner N, Tutt A, Ashworth A. Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol 2005; 5:388-93.
4. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001; 411:366-74.
5. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC and Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917-21.
6. Jagtap P, Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 2005; 4:421-40.
7. Noel G, Giocanti N, Fernet M, Megnin-Chanet F, Favaudon V. Poly(ADP-ribose) polymerase (PARP-1) is not involved in DNA double-strand break recovery. BMC Cell Biol 2003; 4:7.
8. Arnaudeau C, Lundin C, Helleday T. DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells. J Mol Biol 2001; 307:1235-45.
9. Haber JE. DNA recombination: The replication connection. Trends Biochem Sci 1999; 24:271-5.
10. Symington LS. Focus on recombinational DNA repair. EMBO Rep 2005; 6:512-7.
11. Loh VM Jr., Cockcroft XL, Dillon KJ, Dixon L, Drzewiecki J, Eversley PJ, Gomez S, Hoare J, Kerrigan F, Matthews IT, Menear KA, Martin NM, Newton RF, Paul J, Smith GC, Vile J and Whittle AJ. Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase. Bioorg Med Chem Lett 2005; 15:2235-8.
12. Kraakman-van der Zwet M, Overkamp WJ, van Lange RE, Essers J, van Duijn-Goedhart A, Wiggers I, Swaminathan S, van Buul PP, Errami A, Tan RT, Jaspers NG, Sharan SK, Kanaar R and Zdzienicka MZ. Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions. Mol Cell Biol 2002; 22:669-79.
13. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ and Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434:913-7.
14. Gallmeier E, Kern SE. Absence of specific killing of the BRCA2-deficient human cancer cell line CAPAN1 by Poly (ADP-ribose) Polymerase. Cancer Biol Ther 2005; 4:703-6.
15. Griffin RJ, Srinivasan S, Bowman K, Calvert AH, Curtin NJ, Newell DR, Pemberton LC and Golding BT. Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP). J Med Chem 1998; 41:5247-56.
16. Delaney CA, Wang L-Z, Kyle S, White AW, Calvert AH, Curtin NJ, Durkacz, BW, Hostomsky Z, Newell DR. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumour cell lines. Clinical Cancer Res 2000; 6:2860-7.